Skip to main content
Sign In

Dr. Fred Hirsch Lab

CLIA #06D2003207


Dr. Fred Hirsch, MD, PhD, has worked with clinical/ translational research in lung cancer for more than 25 years. His current interest is in biomarker developments for early detection, chemoprevention and treatment of lung cancer. He is also studying markers related to molecular targeted therapies in order to understand the mechanisms of action and resistance of these new therapies, and to be able to select the patients who will benefit from such treatment.

The biomarker studies relate to the development of molecular targeted therapies for chemoprevention and treatment of lung cancer including studies on lung cancer cell lines and tumor tissue from clinical cohots. Within the last years focus has been on identifying biomarkers, which can be used to select lung cancer patients to EGFR tyrosine kinase inhibitors and other EGFR inhibitors. Dr. Hirsch’s laboratory is currently studying biomarkers in multiple clinical trials performed in the US and Europe both in lung and head and neck cancer.

Fred Hirsch CV 

Articles in

Articles in Daily Rx

Articles in Colorado Cancer Blogs

Articles in

Articles in Science Daily 

Articles in The ASCO Post Interview: "The role of genetic mutations in lung cancer"

Contact Info:

12801 E. 17th Ave.L18-8119Aurora, CO

University of Colorado Denver

© The Regents of the University of Colorado, a body corporate. All rights reserved.

All trademarks are registered property of the University. Used by permission only.